Abstract 230P
Background
As far as we know, we have yet to establish the long-term cancer outcomes of partial cystectomy (PC) for urothelial carcinoma. Radical cystectomy (RC) is a complex and risky procedure for muscle invasive bladder cancer (MIBC). In some cases, PC with bilateral pelvic lymph node dissection can be an option in selected patients but may compromise oncologic success. We compared the recurrence patterns and survival rates of patients who had either partial or radical cystectomy for MIBC patients with solitary tumor.
Methods
We identified 30 solitary MIBC patients with downgraded staging below cT2 after TURBT or neoadjuvant systemic therapy at our hospital from 2014 to 2021. They had either partial cystectomy or radical cystectomy and all of them had pathological T staging below pT2. We compare the overall survival, cancer specific survival and recurrence pattern including local recurrence and metastasis.
Results
The median postoperative follow-up period was 5 years, with a range of 1 to 8.5 years. When comparing patients who underwent partial cystectomy to those who underwent radical cystectomy, no significant differences were observed in the 5-year distant recurrence-free survival rates (100% vs 94.5%, p = 0.23) or cancer-specific survival rates (91.7% vs 100%, p = 0.43). Furthermore, there were no instances of extravesical pelvic tumor recurrence in either the partial or radical cystectomy groups postoperatively. Among the patients who underwent partial cystectomy, 6 out of 12 (50%) experienced intravesical recurrence of the tumor, and only 1 out of 12 (5.5%) ultimately required conversion to radical cystectomy.
Conclusions
For patients with solitary muscle-invasive bladder cancer that has been downgraded to a stage below cT2, partial cystectomy is a feasible option as it offers a similar metastasis-free survival and cancer-specific survival rate when compared to radical cystectomy. However, it is crucial to acknowledge that patients who received partial cystectomy remain at risk of experiencing recurrence within the bladder. Therefore, it is imperative to provide these patients with appropriate counseling and ongoing monitoring to address this potential risk.
Clinical trial identification
Not applicable
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract